1
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
--------------
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15 (d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported): April 12, 2001
United Therapeutics Corporation
--------------------------------------------------
(Exact Name of Registrant as Specified in Charter)
Delaware 0-26301 52-1984749
--------------- ------- ----------
(State or Other (Commission (I.R.S. Employer
Jurisdiction of File Number) Identification Number)
Incorporation)
1110 Spring Street
Silver Spring, MD 20910
-------------------------------------------------------- -------------
(Address of Principal Executive Offices) (Zip Code)
Registrant's telephone number, including area code:
(301) 608-9292
-----------------------------------
2
ITEM 5. OTHER EVENTS.
On April 12, 2001, the Registrant issued a press release attached hereto
as Exhibit 99 and incorporated herein.
ITEM 7. FINANCIAL STATEMENTS, PRO FORMA FINANCIAL INFORMATION AND EXHIBITS.
Exhibit No. Description of Exhibit
----------- ----------------------
99 Press release of April 12, 2001
3
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
United Therapeutics Corporation
(Registrant)
Date: April 12, 2001 By: /s/ Martine A. Rothblatt
-------------------------------
Name: Martine A. Rothblatt
Title: Chief Executive Officer
4
Exhibit Index
Exhibit No. Description of Exhibit
----------- ----------------------
99 Press release of April 12, 2001